747412-49-3 | Nvp-auy922

5-(2,4-bis-benzyloxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylicacidethylamide 

  747412-49-3 

[1]JournalofMedicinalChemistry,2008,vol.51,p.196-218

[2]Patent:WO2004/72051,2004,A1.Locationinpatent:Page110

747412-49-3    75-75-2   

5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylicacidethylamidemesylate 

[1]Patent:WO2008/104595,2008,A1.Locationinpatent:Page/Pagecolumn12-13

747412-49-3   

5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylicacidethylamidehydrochloride 

[1]Patent:WO2008/104595,2008,A1.Locationinpatent:Page/Pagecolumn11

cholesterylhemi-4-oxaglutarate 

  747412-49-3   

AUY922-diglycolate-cholesterol 

[1]Patent:WO2017/11685,2017,A1.Locationinpatent:Paragraph0092;0093

747412-49-3    74124-79-1   

N-ε-4-methyltrityl-L-lysine 

  75286-49-6    60-24-2   

5-carboxy-2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)benzoate 

 

C108H153N23O19S2 

 

C108H153N23O19S2 

[1]JournaloftheAmericanChemicalSociety,2017,vol.139,p.9455-9458

Title: Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.

Journal: Immunopharmacology and immunotoxicology 20160101

Title: HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.

Journal: Genes & cancer 20150101

Title: Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.

Journal: Bioorganic & medicinal chemistry letters 20140101

Title: Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120701

Title: Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.

Journal: Anticancer research 20120701

Title: Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20120601

Title: Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands) 20120401

Title: A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein.

Journal: The Journal of biological chemistry 20120106

Title: The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.

Journal: PloS one 20120101

Title: Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

Title: Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.

Journal: Cancer science 20110701

Title: Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.

Journal: Anticancer research 20110401

Title: 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20100501

Title: Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.

Journal: Molecular cancer therapeutics 20100501

Title: Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.

Journal: European journal of haematology 20100401

Title: Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.

Journal: Molecular cancer therapeutics 20100401

Title: (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.

Journal: European journal of cancer (Oxford, England : 1990) 20100201

Title: Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.

Journal: Nuclear medicine and biology 20090401

Title: Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

Journal: Leukemia 20080801

Title: Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20080701

Title: NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

Journal: Cancer research 20080415

Title: 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

Journal: Journal of medicinal chemistry 20080124

Title: NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

Journal: Breast cancer research : BCR 20080101

Title: Eccles, Suzanne A., et al. NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research (2008), 68(8), 2850-2860.

Title: Best OG, et al. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with NSC 118218 against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leuk Lymphoma. 2012 Jul 9.

Title: Moser C, et al. Stoeltzing O.Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res. 2012 Jul;32(7):2551-61.